AB Science's Update on Masitinib and ALS Treatments
AB Science SA has recently provided an essential update regarding its application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS). The European Medicines Agency (EMA) has delivered a negative opinion on this application, which was discussed during a meeting held by the Committee for Medicinal Products for Human Use (CHMP).
Understanding the Current Situation
The application for masitinib was under re-examination by the CHMP following a previous negative assessment issued earlier. This re-review reflects the urgent need to give ALS patients access to promising therapies as soon as possible. The company highlighted the significant clinical findings from the phase 2B/3 study AB10015, which indicated promising results in extending overall survival for ALS patients.
Key Findings from the Phase 2B/3 Study
The clinical data from the AB10015 study demonstrated an increase in median survival by up to six months for those in the primary analysis group. Notably, a subgroup of patients, prior to any significant loss of function, exhibited an impressive twelve-month survival benefit. These outcomes underscore the potential effectiveness of masitinib for treating ALS.
Scientific Advisory Group Insights
A Scientific Advisory Group – Neurology (SAG-N) was integrated into this re-examination process. SAG-N experts agreed on the need to differentiate between normal and fast progressors of the disease, which is crucial for the further design of confirmatory studies involving masitinib and ALS.
Next Steps for AB Science
Even though the current clinical study is recognized as hypothesis-generating, it is insufficient to secure marketing authorization on its own. Therefore, AB Science is focusing on advancing its confirmatory study designs to ensure comprehensive evaluation and data gathering for regulatory approval.
Future Plans and Regulatory Challenges
AB Science also recently received feedback from Health Canada regarding its analysis presented for reconsideration. The agency classified the submitted data as new, thus hampering the re-examination process. Consequently, AB Science decided not to pursue this reconsideration but considers the option to submit a fresh application.
CEO's Commitment to ALS Community
Alain Moussy, CEO and co-founder of AB Science, expressed gratitude to the patients and physicians supporting the re-examination. He emphasized the company's commitment to ensuring that masitinib reaches those who need it most, especially after witnessing positive outcomes from prolonged compassionate use in ALS patients.
About AB Science
Founded in 2001, AB Science specializes in developing targeted protein kinase inhibitors essential for cell signaling pathways. The company focuses on addressing high unmet medical needs, particularly in life-threatening conditions. Its leading compound, masitinib, is already registered for veterinary use, and AB Science is working diligently to bring this treatment to human use across various disease types, including neurological disorders.
Frequently Asked Questions
What is masitinib?
Masitinib is a targeted therapy designed to inhibit specific proteins involved in cell signaling, aimed at treating diseases with high unmet medical needs, such as ALS.
What recent developments occurred regarding masitinib?
AB Science recently faced a negative opinion from the EMA on its conditional marketing authorization application for masitinib in ALS treatment, prompting further studies and re-examinations.
What were the findings of the AB10015 study?
The AB10015 study indicated a median overall survival increase of six months for normal progressors and twelve months for patients before significant functional loss.
What is AB Science's next step after the EMA's decision?
AB Science is focusing on confirmatory studies for masitinib to gather more comprehensive data needed for future regulatory applications.
How can I learn more about AB Science?
You can visit AB Science's official website for more information on their research and developments regarding ALS and other diseases they are targeting.
